Lapatinib and trastuzumab combination shrinks HER2-positive cancer

被引：0
|
作者：
Coles, Charlotte [1 ]
机构：
[1] Cambridge Univ Hosp NHS Trust, Cambridge, England
来源：
BRITISH JOURNAL OF HOSPITAL MEDICINE | 2016年 / 77卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：206 / 206
页数：1
相关论文
共 50 条
  • [31] Combined lapatinib and paclitaxel in HER2-positive breast cancer
    Carlos A. Castañeda
    Henry L. Gomez
    Nature Reviews Clinical Oncology, 2009, 6 : 308 - 309
  • [32] Clinical observation of lapatinib versus continued use of trastuzumab for trastuzumab-resistant HER2-positive advanced breast cancer
    Yin, Yongmei
    Li, Wei
    Huang, Xiang
    Wang, Jian
    Fu, Ziyi
    Li, Jun
    CANCER RESEARCH, 2018, 78 (04)
  • [33] Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer
    Vieira, Claudia
    Borges, Andreia
    Pereira, Filipa F.
    Antunes, Pedro
    Redondo, Patricia
    Antunes, Luis
    Lopes, Jose M.
    Goncalves, Francisco R.
    Borges, Marina
    Bento, Maria J.
    JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY, 2023, 6 (01) : 1 - 9
  • [34] Trastuzumab, not lapatinib, has therapeutic effects on Chinese patients with HER2-positive cholangiocarcinoma
    Hai-Boc Mou
    Wen-Dong Li
    Yan-Jun Shen
    Jun-Ping Shi
    Xiao-Di Guo
    Ming Yao
    Kai Wang
    Ting Zhang
    Hepatobiliary & Pancreatic Diseases International, 2018, 17 (05) : 477 - 479
  • [35] Trastuzumab, not lapatinib, has therapeutic effects on Chinese patients with HER2-positive cholangiocarcinoma
    Mou, Hai-Bo
    Li, Wen-Dong
    Shen, Yan-Jun
    Shi, Jun-Ping
    Guo, Xiao-Di
    Yao, Ming
    Wang, Kai
    Zhang, Ting
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2018, 17 (05) : 477 - 479
  • [36] Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy
    Derakhshani, Afshin
    Rezaei, Zohreh
    Safarpour, Hossein
    Sabri, Morteza
    Mir, Atefeh
    Sanati, Mohammad Amin
    Vahidian, Fatemeh
    Moghadam, Ali Gholamiyan
    Aghadoukht, Ali
    Hajiasgharzadeh, Khalil
    Baradaran, Behzad
    JOURNAL OF CELLULAR PHYSIOLOGY, 2020, 235 (04) : 3142 - 3156
  • [37] Tolerability of the combination of lapatinib and trastuzumab in older patients with HER2 positive metastatic breast cancer
    O'Connor, Tracey
    Soto-Perez-de-Celis, Enrique
    Blanchard, Suzette
    Chapman, Andrew
    Kimmick, Gretchen
    Muss, Hyman
    Luu, Thehang
    Waisman, James R.
    Li, Daneng
    Mortimer, Joanne
    Yuan, Yuan
    Somlo, George
    Stewart, Daphne
    Katheria, Vani
    Levi, Abrahm
    Hurria, Arti
    CANCER RESEARCH, 2018, 78 (04)
  • [38] A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer
    Larsen, Pia Bukmann
    Kumler, Iben
    Nielsen, Dorte Lisbet
    CANCER TREATMENT REVIEWS, 2013, 39 (07) : 720 - 727
  • [39] Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB trial)
    Guarneri, Valentina
    Frassoldati, Antonio
    Piacentini, Federico
    Jovic, Gordana
    Giovannelli, Simona
    Oliva, Cristina
    Conte, PierFranco
    CLINICAL BREAST CANCER, 2008, 8 (02) : 192 - 194
  • [40] Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer
    Crown, J.
    Kennedy, M. J.
    Tresca, P.
    Marty, M.
    Espie, M.
    Burris, H. A.
    DeSilvio, M.
    Lau, M. R.
    Kothari, D.
    Koch, K. M.
    Dieras, V.
    ANNALS OF ONCOLOGY, 2013, 24 (08) : 2005 - 2011
12345